Imalumab

Imalumab is an monoclonal antibody against macrophage inhibitory factor (MIF).[1] Currently it is being tested in Phase 2a clinical trials[2] for colorectal cancer, in development by [[Baxalta now Shire]].

References

  1. ↑ https://www.clinicaltrials.gov/ct2/show/NCT02448810
  2. ↑ https://www.clinicaltrials.gov/ct2/show/NCT02448810
This article is issued from Wikipedia - version of the 9/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.